Serum islet cell autoantibodies during interferon α treatment in patients with HCV-genotype 4 chronic hepatitis

Gamal Badra, Imam Waked, Carlo Selmi, Saleh M. Saleh, Ahmed El-Shaarawy, Mahmoud Lotfy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 naïve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.

Original languageEnglish (US)
Pages (from-to)11-15
Number of pages5
JournalClinical and Developmental Immunology
Volume13
Issue number1
DOIs
StatePublished - Mar 1 2006

Fingerprint

Chronic Hepatitis
Islets of Langerhans
Hepacivirus
Autoantibodies
Interferons
Genotype
Serum
Chronic Hepatitis C
Therapeutics
End Stage Liver Disease
Glucose Intolerance
Virus Diseases
Indirect Fluorescent Antibody Technique
Infection
Glucose
Incidence

Keywords

  • Antiviral treatment
  • Chronic hepatitis C
  • Genotype 4
  • Glucose tolerance

ASJC Scopus subject areas

  • Immunology
  • Cell Biology
  • Developmental Biology

Cite this

Serum islet cell autoantibodies during interferon α treatment in patients with HCV-genotype 4 chronic hepatitis. / Badra, Gamal; Waked, Imam; Selmi, Carlo; Saleh, Saleh M.; El-Shaarawy, Ahmed; Lotfy, Mahmoud.

In: Clinical and Developmental Immunology, Vol. 13, No. 1, 01.03.2006, p. 11-15.

Research output: Contribution to journalArticle

Badra, Gamal ; Waked, Imam ; Selmi, Carlo ; Saleh, Saleh M. ; El-Shaarawy, Ahmed ; Lotfy, Mahmoud. / Serum islet cell autoantibodies during interferon α treatment in patients with HCV-genotype 4 chronic hepatitis. In: Clinical and Developmental Immunology. 2006 ; Vol. 13, No. 1. pp. 11-15.
@article{3d54dd24b24744c5b0e8f46a4fa3c0a9,
title = "Serum islet cell autoantibodies during interferon α treatment in patients with HCV-genotype 4 chronic hepatitis",
abstract = "Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 na{\"i}ve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5{\%}) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32{\%}) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.",
keywords = "Antiviral treatment, Chronic hepatitis C, Genotype 4, Glucose tolerance",
author = "Gamal Badra and Imam Waked and Carlo Selmi and Saleh, {Saleh M.} and Ahmed El-Shaarawy and Mahmoud Lotfy",
year = "2006",
month = "3",
day = "1",
doi = "10.1080/17402520600557867",
language = "English (US)",
volume = "13",
pages = "11--15",
journal = "Journal of Immunology Research",
issn = "2314-8861",
publisher = "Hindawi Publishing Corporation",
number = "1",

}

TY - JOUR

T1 - Serum islet cell autoantibodies during interferon α treatment in patients with HCV-genotype 4 chronic hepatitis

AU - Badra, Gamal

AU - Waked, Imam

AU - Selmi, Carlo

AU - Saleh, Saleh M.

AU - El-Shaarawy, Ahmed

AU - Lotfy, Mahmoud

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 naïve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.

AB - Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 naïve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.

KW - Antiviral treatment

KW - Chronic hepatitis C

KW - Genotype 4

KW - Glucose tolerance

UR - http://www.scopus.com/inward/record.url?scp=33645872400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645872400&partnerID=8YFLogxK

U2 - 10.1080/17402520600557867

DO - 10.1080/17402520600557867

M3 - Article

C2 - 16603440

AN - SCOPUS:33645872400

VL - 13

SP - 11

EP - 15

JO - Journal of Immunology Research

JF - Journal of Immunology Research

SN - 2314-8861

IS - 1

ER -